RS62827B1 - Tretman staračke degeneracije žute mrlje koja ima malu aktivnu leziju neovaskularizacije sudovnjače - Google Patents

Tretman staračke degeneracije žute mrlje koja ima malu aktivnu leziju neovaskularizacije sudovnjače

Info

Publication number
RS62827B1
RS62827B1 RS20220058A RSP20220058A RS62827B1 RS 62827 B1 RS62827 B1 RS 62827B1 RS 20220058 A RS20220058 A RS 20220058A RS P20220058 A RSP20220058 A RS P20220058A RS 62827 B1 RS62827 B1 RS 62827B1
Authority
RS
Serbia
Prior art keywords
treatment
macular degeneration
related macular
choroidal neovascularization
age related
Prior art date
Application number
RS20220058A
Other languages
English (en)
Inventor
Oliver Zeitz
Olaf Sowade
Haiyan Wu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55069121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62827(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2014/093548 external-priority patent/WO2016090590A1/en
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of RS62827B1 publication Critical patent/RS62827B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20220058A 2014-12-11 2015-12-10 Tretman staračke degeneracije žute mrlje koja ima malu aktivnu leziju neovaskularizacije sudovnjače RS62827B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2014/093548 WO2016090590A1 (en) 2014-12-11 2014-12-11 Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion
CN2015089251 2015-09-09
EP15819965.3A EP3230316B1 (en) 2014-12-11 2015-12-10 Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
PCT/US2015/065022 WO2016094673A1 (en) 2014-12-11 2015-12-10 Treatment of age related macular degeneration with a small active choroidal neovascularization lesion

Publications (1)

Publication Number Publication Date
RS62827B1 true RS62827B1 (sr) 2022-02-28

Family

ID=55069121

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220058A RS62827B1 (sr) 2014-12-11 2015-12-10 Tretman staračke degeneracije žute mrlje koja ima malu aktivnu leziju neovaskularizacije sudovnjače

Country Status (16)

Country Link
US (2) US20170326106A1 (sr)
EP (2) EP3230316B1 (sr)
JP (3) JP7320919B2 (sr)
CN (3) CN112826934A (sr)
AU (3) AU2015360496B2 (sr)
CA (1) CA2970315C (sr)
DK (1) DK3230316T3 (sr)
ES (1) ES2907148T3 (sr)
HR (1) HRP20220066T1 (sr)
HU (1) HUE057653T2 (sr)
LT (1) LT3230316T (sr)
PL (1) PL3230316T3 (sr)
PT (1) PT3230316T (sr)
RS (1) RS62827B1 (sr)
SI (1) SI3230316T1 (sr)
WO (1) WO2016094673A1 (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
HRP20220066T1 (hr) 2014-12-11 2022-04-15 Bayer Healthcare Llc Liječenje makularne degeneracije povezane sa starenjem s malom aktivnom koroidnom neovaskularizacijskom lezijom
WO2016100851A1 (en) * 2014-12-18 2016-06-23 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
IL276383B2 (en) * 2018-02-06 2024-01-01 Hoffmann La Roche Treatment of ophthalmological diseases
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733674B2 (en) 1996-10-25 2001-05-24 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
CZ302689B6 (cs) 1999-06-08 2011-09-07 Regeneron Pharmaceuticals, Inc. Izolovaná molekula nukleové kyseliny, fúzní polypeptid jí kódovaný, vektor s jejím obsahem, systém vektor-hostitel pro produkci fúzního polypeptidu a zpusob jeho prípravy, antagonista dimerního VEGF a použití
CA2437563C (en) * 2001-02-06 2010-03-23 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
EP2663325A1 (en) * 2011-01-13 2013-11-20 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
HRP20220066T1 (hr) 2014-12-11 2022-04-15 Bayer Healthcare Llc Liječenje makularne degeneracije povezane sa starenjem s malom aktivnom koroidnom neovaskularizacijskom lezijom

Also Published As

Publication number Publication date
EP3985023A1 (en) 2022-04-20
ES2907148T3 (es) 2022-04-22
CN114306575A (zh) 2022-04-12
HUE057653T2 (hu) 2022-05-28
EP3230316B1 (en) 2022-01-05
CN112826934A (zh) 2021-05-25
HRP20220066T1 (hr) 2022-04-15
US20170326106A1 (en) 2017-11-16
PT3230316T (pt) 2022-02-24
SI3230316T1 (sl) 2022-05-31
JP2021004262A (ja) 2021-01-14
AU2021245214B2 (en) 2024-05-02
AU2015360496A1 (en) 2017-05-25
CN106999511A (zh) 2017-08-01
EP3230316A1 (en) 2017-10-18
LT3230316T (lt) 2022-02-10
JP2022183183A (ja) 2022-12-08
PL3230316T3 (pl) 2022-05-02
WO2016094673A1 (en) 2016-06-16
AU2021107575A4 (en) 2022-01-06
DK3230316T3 (da) 2022-03-28
JP2017537117A (ja) 2017-12-14
CA2970315A1 (en) 2016-06-16
AU2015360496B2 (en) 2021-09-30
US20190381008A1 (en) 2019-12-19
AU2021245214A1 (en) 2021-11-04
JP7320919B2 (ja) 2023-08-04
CA2970315C (en) 2023-08-22

Similar Documents

Publication Publication Date Title
HUE057653T2 (hu) Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése
IL283561B (en) Methods for treating eye diseases
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
IL252159A0 (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
HK1246179A1 (zh) 治療視網膜疾病的方法
IL247942A0 (en) Compositions and methods for drops in macular edema as a result of diabetes
IL246791A0 (en) Compositions and methods for treating eye diseases
IL268850A (en) Combinations of 4-pyrimidinesulfamide derivatives with active ingredients for the treatment of endothelin-related diseases
GB201403260D0 (en) Treatment of retinal degeneration using gene therapy
HK1217490A1 (zh) 黃斑變性治療中的新穎捕獲劑
IL248016A0 (en) Effect of lipophilic nutrients on diabetic eye disease
ZA201704793B (en) Treatment of retinal degeneration using progenitor cells
SG11201608257RA (en) A device for a medical treatment of a sclera
PL3233174T3 (pl) Wewnątrzgałkowe dostarczanie bioaktywnych cząsteczek za pomocą jontoforezy
PT2953596T (pt) Técnica para tratamento fotodisruptivo por múltiplos impulsos de um material
EP3089748A4 (en) Treating ocular neovascularization
GB201412578D0 (en) Treatment of neurological diseases
IL261891A (en) Active retinal implant
GB201413330D0 (en) Agricultural treatment
GB201400839D0 (en) Agricultural treatment
GB201406602D0 (en) Biocompatible crotch stiffener